Medical review (Berlin, Germany)最新文献_第5页

Recent advances in understanding the relationship between lipid metabolism and immune escape in the tumor microenvironment of gastric cancer. 胃癌微环境中脂质代谢与免疫逃逸关系的研究进展。

Medical review (Berlin, Germany) Pub Date : 2025-10-16 eCollection Date: 2025-10-01 DOI: 10.1515/mr-2025-0035

Qin Zhan, Haoxiang Ni, Ming Zhou, Xiaozhe Mao, Yifan Ouyang, Tongguo Shi, Rui Li

引用次数: 0

Unfolding ecDNA as a pan-cancer therapeutic target. 揭示ecDNA作为泛癌症治疗靶点。

Medical review (Berlin, Germany) Pub Date : 2025-10-07 eCollection Date: 2025-10-01 DOI: 10.1515/mr-2025-0050

Yang Zhang, Ruirui Chen, Haiyun Gan

引用次数: 0

Lac-Phe: a central metabolic regulator and biomarker. Lac-Phe：一种中枢代谢调节剂和生物标志物。

Medical review (Berlin, Germany) Pub Date : 2025-09-18 eCollection Date: 2025-10-01 DOI: 10.1515/mr-2025-0030

Taikang Yao, Guolin Alexander Wen, Zhenchao Wu, Ning Shen

引用次数: 0

Orchestration of tertiary lymphoid structures: decoding developmental mechanisms for next-generation cancer immunotherapies. 三级淋巴结构的编排：解码下一代癌症免疫治疗的发育机制。

Medical review (Berlin, Germany) Pub Date : 2025-09-12 eCollection Date: 2025-10-01 DOI: 10.1515/mr-2025-0037

Wenqin Hao, Ying Zhao

引用次数: 0

Transcript diversity in aging: cryptic transcription and splicing. 衰老过程中的转录多样性：隐式转录和剪接。

Medical review (Berlin, Germany) Pub Date : 2025-08-27 eCollection Date: 2025-10-01 DOI: 10.1515/mr-2025-0032

Brenna S McCauley, Nicholas Nikoloutsos, Weiwei Dang

引用次数: 0

Outcomes of revised portoenterostomy for postoperative bile lakes in patients with biliary atresia. 改良门肠造口术治疗胆道闭锁患者术后胆湖的疗效。

Medical review (Berlin, Germany) Pub Date : 2025-08-19 eCollection Date: 2025-10-01 DOI: 10.1515/mr-2025-0024

Yu Tian, Jiayi Feng, Mao Ye, Zhen Chen, Yuanyuan Geng, Xiaojin He, Shuai Chen, Xu Li, Long Li

{"title":"Outcomes of revised portoenterostomy for postoperative bile lakes in patients with biliary atresia.","authors":"Yu Tian, Jiayi Feng, Mao Ye, Zhen Chen, Yuanyuan Geng, Xiaojin He, Shuai Chen, Xu Li, Long Li","doi":"10.1515/mr-2025-0024","DOIUrl":"10.1515/mr-2025-0024","url":null,"abstract":"Objectives: Kasai portoenterostomy (KPE) is the primary treatment for biliary atresia (BA). However, postoperative complications such as cholangitis with bile lake formation frequently lead to liver failure. This study aimed to evaluate the therapeutic efficacy and significance of revision portoenterostomy in patients with bile lakes at the porta hepatis following KPE.Methods: A retrospective analysis of patients with BA who underwent revision portoenterostomy from January 2011 to December 2021 was conducted. Patient data, including laboratory tests, imaging findings, and follow-up records, were comprehensively reviewed. The jaundice clearance rate and autologous liver survival rate were assessed using the Kaplan-Meier method. The Cox proportional hazards model was employed to identify factors influencing revision portoenterostomy outcomes.Results: Twenty patients with cholangitis and bile lakes underwent revision portoenterostomy. Sixteen patients (80 %) achieved jaundice clearance, and 14 (60 %) attained autologous liver survival, resulting in an overall survival rate of 90 %. All patients with refractory cholangitis preoperatively showed improvement following revision portoenterostomy. Additionally, the revision portoenterostomy procedure did not lead to increased blood loss or extended operation times in subsequent liver transplants.Conclusions: Revision portoenterostomy for patients with bile lakes effectively alleviates intractable cholangitis and can delay or eliminate the necessity for liver transplantation.","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 5","pages":"412-420"},"PeriodicalIF":0.0,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12558036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145395172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spatio-temporal processes in autophagosome-lysosome fusion. 自噬体-溶酶体融合的时空过程。

Medical review (Berlin, Germany) Pub Date : 2025-06-19 eCollection Date: 2025-08-01 DOI: 10.1515/mr-2024-0095

Shizuo Liu, Huan Yan, Jiajie Diao, Shen Zhang, Qing Zhong

{"title":"Spatio-temporal processes in autophagosome-lysosome fusion.","authors":"Shizuo Liu, Huan Yan, Jiajie Diao, Shen Zhang, Qing Zhong","doi":"10.1515/mr-2024-0095","DOIUrl":"10.1515/mr-2024-0095","url":null,"abstract":"Macroautophagy/autophagy is a lysosome-dependent degradation process involved in cellular energy metabolism, recycling and quality control. Autophagy is a highly dynamic and precisely regulated process, which contains four major steps: autophagic membrane initiation and cargo recognition, autophagosome formation, autophagosome-lysosome fusion and lysosomal degradation. During the terminal phase of autophagy, the merging of the autophagosome and lysosome membranes is critical for the effective breakdown of sequestered cargoes. However, the participated molecules and the interplay among them have not been fully uncovered. The spatiotemporal property of these molecules is crucial for maintaining the orderly fusion of autophagosomes and lysosomes, otherwise it may lead to fusion disorders. In this article, we tend to summarize the molecules mediating autophagosome-lysosome fusion into two categories: effector molecules and regulatory molecules. The effector molecules are soluble N-ethylmaleimide-sensitive factor attachment protein receptor and tethering proteins, and the latter category contains phosphatidylinositol, Rab GTPases and ATG8-family proteins. The spatio-temporal properties of these autophagosome-lysosome fusion mediating molecules will be featured in this review.","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 4","pages":"297-317"},"PeriodicalIF":0.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12362064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can chimeric antigen receptors - based therapy bring a gleam of hope for thyroid-associated ophthalmopathy and other autoimmune diseases? 以嵌合抗原受体为基础的治疗能给甲状腺相关眼病和其他自身免疫性疾病带来一线希望吗？

Medical review (Berlin, Germany) Pub Date : 2025-04-14 eCollection Date: 2025-08-01 DOI: 10.1515/mr-2024-0099

Weiyi Zhou, Xinyu Zhu, Yongquan Shi

{"title":"Can chimeric antigen receptors - based therapy bring a gleam of hope for thyroid-associated ophthalmopathy and other autoimmune diseases?","authors":"Weiyi Zhou, Xinyu Zhu, Yongquan Shi","doi":"10.1515/mr-2024-0099","DOIUrl":"10.1515/mr-2024-0099","url":null,"abstract":"Thyroid-associated ophthalmopathy (TAO), also known as Graves' ophthalmopathy (GO) is an autoimmune disease (AD) with abnormal thyroid function typically. Currently, intravenous glucocorticoid therapy remains the first-line treatment for moderate-to-severe active TAO. Second-line treatments, including immunosuppressants and biological agents, are being explored in depth. However, like other ADs, the adverse effects of these therapies, little impact on long-term sequelae, and the irreversible progression of the disease remain significant limitations. As a result, the development of new therapeutic strategies for TAO is essential. Chimeric antigen receptors (CAR)-based adoptive cell therapy has emerged as an innovative approach for ADs treatment, capitalizing on its principles of genetically modifying immune cells to specifically target pathogenic cells. This approach aims to reduce autoimmune response or eliminate effective cells, CAR-based therapies of both T-cell-mediated and B-cell-mediated ADs have shown promising results in wide clinical trial. CAR-based therapy obviously become a rising star on refractory and relapsed ADs. TAO is no exception in terms of the potential for improvement through CAR-based therapy. However, the success of CAR-based therapy in TAO depends critically on identifying appropriate targets. Selected targets need to be coverage to ensure the therapeutic efficiency while specificity to preserve safety. Furthermore, the target cells must be relevant to the pathogenesis of TAO. Except target selection, adopting advanced and effective strategies for CAR design is also crucial. For example, dual-target approaches involving thyroid-stimulating hormone receptor (TSHR) or insulin-like growth factor-1 receptor (lGF-1R), off-the-shelf CAR-based cells, or leveraging artificial intelligence (Al) to predict optimal targets could enhance the specificity and effectiveness of CAR-based, therapies in TAO treatment.","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 4","pages":"339-347"},"PeriodicalIF":0.0,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12362059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence-driven transformative applications in disease diagnosis technology. 人工智能在疾病诊断技术中的变革性应用。

Medical review (Berlin, Germany) Pub Date : 2025-04-11 eCollection Date: 2025-10-01 DOI: 10.1515/mr-2024-0097

Junyu Zhou, Sunmin Park, Sihan Dong, Xiaoying Tang, Xunbin Wei

{"title":"Artificial intelligence-driven transformative applications in disease diagnosis technology.","authors":"Junyu Zhou, Sunmin Park, Sihan Dong, Xiaoying Tang, Xunbin Wei","doi":"10.1515/mr-2024-0097","DOIUrl":"10.1515/mr-2024-0097","url":null,"abstract":"The integration of artificial intelligence (AI) in medical diagnostics represents a transformative advancement in healthcare, with projected market growth reaching $188 billion by 2030. This comprehensive review examines the latest developments in AI-driven diagnostic technologies across multiple disease domains, particularly focusing on cancer, Alzheimer's disease (AD), and diabetes. Through systematic bibliometric analysis using GraphRAG methodology, we analyzed research publications from 2022 to 2024, revealing the distribution and impact of AI applications across various medical fields. In cancer diagnostics, AI systems have achieved breakthrough performances in analyzing medical imaging and molecular data, with notable advances in early detection capabilities across 19 different cancer types. For AD diagnosis, AI-powered tools have demonstrated up to 90 % accuracy in risk detection through non-invasive methods, including speech pattern analysis and blood-based biomarkers. In diabetes care, AI-integrated systems incorporating deep neural networks and electronic nose technology have shown remarkable accuracy in predicting disease onset before clinical manifestation. These developments collectively indicate a paradigm shift toward more precise, efficient, and accessible diagnostic approaches. However, challenges remain in standardization, data quality, and clinical implementation. This review synthesizes current progress while highlighting the potential for AI to revolutionize medical diagnostics through enhanced accuracy, early detection, and personalized patient care.","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 5","pages":"353-377"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12558038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145395744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Target discovery-directed pharmacological mechanism elucidation of bioactive natural products. 靶点发现导向的生物活性天然产物的药理学机制阐明。

Medical review (Berlin, Germany) Pub Date : 2025-03-06 eCollection Date: 2025-08-01 DOI: 10.1515/mr-2024-0076

Zixuan Zhen, Lina Yin, Tingting Niu, Asma Rehman, Yang Liu, Kewu Zeng

{"title":"Target discovery-directed pharmacological mechanism elucidation of bioactive natural products.","authors":"Zixuan Zhen, Lina Yin, Tingting Niu, Asma Rehman, Yang Liu, Kewu Zeng","doi":"10.1515/mr-2024-0076","DOIUrl":"10.1515/mr-2024-0076","url":null,"abstract":"Natural products, the most important chemical library with magical structures and unique functions, have long been playing significant roles in contributing to the discovery of novel drugs. The complexity and diversity of natural products present great challenges regarding the exploration of their potential targets. Identifying the targets of natural products not only enhances our understanding of biological functions and molecular mechanisms, but also paves the way for discovering novel lead compounds for disease treatment. Recent advances in technologies like chemical biology, structural biology, and artificial intelligence have provided powerful tools for pinpointing natural product target and unraveling molecular mechanisms. This review aims to comprehensively summarize the innovative strategies employed in recent years to identify natural product targets, and evaluate their impact on biological pathways by modulating target functions for pharmacological effects. Moreover, we also discuss the challenges encountered in this field and outline future research prospects, aiming to offer guidance for researchers in natural product chemical biology.","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 4","pages":"277-296"},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12362066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0